Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus Temozolomide in Newly Diagnosed Glioblastoma
NCT00616005Phase 2Completed
- Sponsor
- Duke University
- Start
- Nov 2005
- Primary completion
- Jul 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in glioblastoma (GBM), sponsored by Duke University. Started Nov 2005; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00616005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616005.